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Abstract
Objective The objective of the present study is to analyze
prognostic factors affecting survival of patients receiving ste-
reotactic radiosurgery (SRS) for second brain metastatic event
(SBME) following initial treatment with whole brain irradia-
tion (WBI), surgical resection, or previous SRS.
Methods The 88 patients treated with SRS for SBME at
Philadelphia CyberKnife between January 2006 and October
2013 were included in the study group. Cox proportional-
hazards regression was used to identify prognostic factors that
significantly impacted survival from the time of SRS for
SBME. Independent variables considered in survival analysis
included primary disease, first brain metastatic event (FBME)
treatment type, age, gender, number of brain metastases at
SBME, Karnofsky performance status (KPS), recursive
partitioning analysis (RPA), and presence of extracranial
metastasis.
Results The median survival for all patients was
7.31 months. Log-rank comparison of Kaplan-Meier sur-
vival curves revealed significant impact by Karnofsky
performance status (p = 0.003), RPA class (p = 0.008),
age (p = 0.014), and FBME treatment type (p = 0.010).
Median survival was longer for patients who had not pre-
viously received WBI (14.7 months). Median survival
was further increased in patients who had not received
previous WBI and demonstrated KPS scores of 70–100
(19.5 months). Patients who received WBI prior to
SBME treatment experienced a pronounced decrement in
median survival (5.7 months), yet patients in this group
who demonstrated strong KPS scores (80–100) experi-
enced significantly increased survival (15.5 months).
Conclusions The outcomes of SRS for SBME are most
favorable for patients who have not received previous
WBI or who have maintained higher performance status
despite previous WBI.
Keywords Brain metastasis . Stereotactic radiosurgery
(SRS) .Whole brain irradiation (WBI) . CyberKnife
Introduction
The clinical management of brain metastases has long focused
on local brain control for maintenance of neurologic function,
since survival has been limited with whole brain radiation for
the primary treatment of multiple metastases. [1] Improved
survival and quality of life has been made possible through
the development of improved diagnostic tools, surgical tech-
niques, and highly precise stereotactic radiosurgery (SRS) op-
tions. [1] Choosing high-tech and costly treatment should be
reserved for those most likely to benefit from that treatment.
Therefore, survival prediction tools using clinical prognostic
factors best guide treatment recommendations.
New cancer diagnoses exceed 1.6 million per year as of
2016 [2]. The rate of brain metastases from all cancers is
approximately 100,000–170,000 per year or nearly 10% of
all patients and as high as 25% in lung cancer patients [3].
Patients are living longer due to improvements in systemic
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therapy, leading to a higher prevalence of brain metastasis,
which remains a sanctuary site for most drugs [3]. The treat-
ment of brain metastases has historically been limited to sur-
gical resection and/or whole-brain radiotherapy (WBRT),
with survival of non-surgical candidates approximately 3–
4 months [4]. With the development of more precise treatment
modalities like SRS, the inherent long-term risk of neuro-
cognitive decline fromWBRTcan be avoided [1]. In addition,
brain control and possibly survival is enhanced with limited
brain metastatic disease after surgery or whole brain radiation
with SRS as adjuvant or boost [5].
While there exist multiple diagnosis-specific survival
prediction tools for patients presenting with first brain
metastatic event (FBME), survival data for patients
experiencing a second brain metastatic event (SBME) is
lacking. The Radiation Therapy Oncology Group
(RTOG), using recursive partitioning analysis (RPA),
formed a regression tree based on significant prognostic
factors from 18 pretreatment and 3 treatment factors
from completed trials of patients with brain metastases
treated with whole brain radiation [6]. Following the ver-
ification of the RPA prognostic index, further refinement
based on treatment was developed for radiosurgery with
the Score Index for Radiosurgery (SIR). The SIR was
developed based on classical parameters including age,
Karnofsky performance status, systemic disease control,
number of intracranial lesions, and size of lesions [7].
Lorenzoni et al. simplified this system using only the
Karnofsky performance status, presence of extracranial
metastases, and primary tumor control as prognostic fac-
tors to estimate prognosis [8]. Lorenzoni’s prognostic
assessment index, the Basic Score for Brain Metastases
(BSBM), was shown to be equivalent to the SIR but in
simplified form.
The most useful prognostic assessment index, the
Graded Prognostic Assessment (GPA) index, reported by
Sperduto et al., compared the existing prognostic indices
including their new GPA index using data from 1960
treated patients in the RTOG database. The GPA index,
similar to previous indices, includes age, Karnofsky per-
formance status, and extracranial metastases as well as
number of brain metastases [9]. Sperduto et al. updated
their GPA index to a Diagnosis-Specific Graded
Prognostic Assessment (DS-GPA), with diagnosis-
specific prognostic factors estimating survival times
[10]. The DS-GPA provides the most accurate estimates
of survival from the time of FBME treatment but was not
designed to provide estimates for patients experiencing
SBME.
The purpose of the present study is to analyze prognostic
factors affecting survival of patients receiving SRS for SBME
following initial treatment with WBI, surgical resection, or
previous SRS for FBME.
Methods
Patient review
All patients treated for brain metastasis with SRS at
Philadelphia CyberKnife between January 2006 and
October 2013 were reviewed (229 patients). Only patients
treated with SRS for SBME were included in the study
group. The study group consisted of 88 patients who re-
ceived one of the following: SRS for SBME ≥2 months
after WBI, surgical resection, or SRS for FBME and for
whom follow-up/survival information was available. Only
three patients were lost to follow-up.
Data collection
Further data was collected on the 88 patients that received
SRS for SBME on this IRB-approved study. Selection of
prognostic factors of interest was guided by established prog-
nostic indices for initial brain metastasis treatment [6–10].
Pretreatment and treatment factors evaluated include age, pri-
mary cancer type, presence of extracranial metastasis, FBME
treatment type, Karnofsky performance status (KPS), recur-
sive partitioning analysis (RPA), number of intracranial le-
sions at the time of SBME, total SRS clinical treatment vol-
ume (CTV), dose and number of fractions, and treatment mar-
gins. Dose prescription was guided by size of the brain metas-
tasis as per the Radiation Therapy Oncology Group (RTOG)
studies. Follow-up and survival data was collected through
various sources including Philadelphia CyberKnife charts, re-
ferring physician charts, Crozer-Keystone Health System
electronic medical records, and obituaries. Patients were
followed every 3 months by the patient’s neurosurgeon, radi-
ation oncologist, or medical oncologist. Date of death or last
follow-up was recorded for all patients.
Statistical analysis
Descriptive statistics were used to characterize the study group
in terms of demographics and treatment characteristics, includ-
ing mean, SD, median, and range for continuous variables, as
well as frequencies and percentages for categorical variables.
Univariate cox proportional-hazards modeling was used to
identify prognostic factors significantly impacting survival
from the time of SRS treatment for SBME. Hazard ratios were
estimated, along with 95% confidence intervals. Multivariable
regression modeling was accomplished using cox regression
and considering variables significant in the univariate analysis
at the 0.20 level, followed bymanually removing factors one at
a time on the basis of least significance, until only those re-
maining demonstrate significance at the 0.10 level. Kaplan-
Meier survival estimates were then generated for all patients
and for prognostic subgroups identified in the cox regression
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analysis. Comparisons in overall survival by group were ac-
complished using log-rank statistics. Finally, median survival
and interquartile range estimates based onKaplan-Meier meth-
odology are presented for important subsets of patients identi-
fied by multiple predictors.
Results
Demographics
Themedian andmean ages of the patient populationwere 59.3
and 59.6 years at the time of SBME treatment with 65%
female and 35% male patients. More than 50% of the study
group had primary lung cancer with multiple other cancers
observed. Over 70% of patients had WBI as part of FMBE
(Table 1). Median time from WBI to SRS for SBME was
8.5 months (2.2–38.4 months). The median planning target
volume (PTV) dose was 20 Gy (13.5–30 Gy) delivered in
one fraction (one to five fractions) with a median 1.25-mm
margin around the clinical target volume (CTV). Additional
treatment characteristics are presented in Table 2.
Overall survival
Kaplan-Meier estimates showed 1- and 2-year actuarial sur-
vival of all patients of 36 and 16%, respectively (Fig. 1). At
the last follow-up, there were 14 patients living of the 88 total
patients. There were four patients alive after the 3-year follow-
up and one patient alive after the 6-year follow-up. Log-rank
tests identified prognostic factors with significant impact on
survival. Of the pretreatment factors analyzed, RPA class, age,
previousWBI, andKPS score impacted survival, with p values
of 0.008, 0.014, 0.010, and 0.003, respectively (Figs. 2, 3, 4,
Table 1 Patient demographics
Variable Category Frequency Percent
Age Median 59.3 years (range 32.8–86.2 years)
Mean 59.6 years (SD ±11.44 years)
Sex Male 31 35.2
Female 57 64.8








KPS score 90–100 13 14.8
70–80 42 47.7
<70 33 37.5
No. of brain metastasis 1 31 35.2
2–3 39 44.3
>3 18 20.5
Extracranial metastasis Present 39 44.3
Not present 49 55.7
RPA class 1 25 28.4
2 30 34.1
3 33 37.5




characteristics Variable Median (range)
CTV volume (cc) 2.64 (0.09–52.44)
PTV volume (cc) 3.69 (0.16–52.44)
Margin (mm) 1.25 (0–3.0)
PTV dose (Gy) 20 (13.5–30)
Fractions 1 (1–5)
No. of beams 134 (53–415)
Isodose (%) 70 (54–82)
BED (Gy) 50.4 (19.6–65.1)
Fig. 1 Kaplan-Meier overall survival estimates for all patients
Fig. 2 Kaplan-Meier overall survival estimates for all patients by RPA
class (p = 0.008)
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and 5). Number of brain metastasis at time of SBME, presence
of extra-cranial metastasis, and primary diagnosis were not
significant prognosticators (Table 3). Multivariate analysis re-
vealed that only KPS (p = 0.001) and age (p = 0.011) were
significant when all significant factors were added to the
model.
Recipients of previous WBI had 1- and 2-year actuarial
survival of 22.6 and 8.1% while patients who did not receive
WBI experienced 1- and 2-year actuarial survival of 57.7 and
23%. KPS scores were stratified into three groups defined by
previous literature review: <70, 70–80, and 90–100 [9, 10].
Lowest KPS score (<70) resulted in markedly decreased 1-
and 2-year actuarial survival compared with higher scores
(Table 4).
Median survival
The overall median survival of the 88 patients receiving SRS
for SBMEwas 7.3 months (IQR 3.3–14.6 months). Low KPS
score (<70) at the time of SBME treatment had a significant
detrimental impact on survival, lowering median survival to
4.08 months (IQR 1.1–7.9 months) compared to 8.83 months
(IQR 4.0–18.1 months) for patients with KPS 70–80 and
16.01 months (IQR 13.3–22.9 months) for patients with
KPS 90–100. Patient age proved to be a significant prognos-
ticator when patients were grouped above and below 50 years.
Younger patients demonstrated significant survival decrement
with a median survival of 4.5 months (IQR 0.9–8.9 months)
comparedwith 7.7months (IQR 3.7–16.5months) for patients
50 and older. RPA class significantly predicted survival with
Fig. 4 Kaplan-Meier overall survival estimates for all patients by first
BM treatment type (p = 0.01)
Fig. 3 Kaplan-Meier overall survival estimates for all patients by age
group (p = 0.01) Fig. 5 Kaplan-Meier overall survival estimates for all patients by KPS
(p = 0.003)
Table 3 Results from univariate cox proportional-hazards modeling of






Age <50 2.096 1.164 3.777 0.014
>50a 1.000 – – –
ECM No 0.688 0.436 1.084 0.107
Yesa 1.000 – – –
WBI No 0.456 0.246 0.847 0.010
Yesa 1.000 – – –
KPS score <70 0.336 0.163 0.694 0.003
70–80 0.466 0.283 0.767 0.003
90–100a 1.000 – – –
No. of mets 1 1.139 0.604 2.150 0.730
2–3 1.344 0.724 2.496 0.399
>3a 1.000 – – –
Primary
diagnosis
Breast 1.443 0.601 3.462 0.412
Colorectal 0.957 0.345 2.656 0.933
Lung 1.260 0.61 2.602 0.532
Melanoma 2.196 0.776 6.214 0.138
Othera 1.000 – – –
RPA 1 0.367 0.203 0.665 0.001
2 0.484 0.284 0.824 0.008
3a 1.000 – – –
a Reference category
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median survivals of 11.7, 8.3, and 4.1 months for classes 1, 2,
and 3, respectively.
Subgroup analysis by previous WBI and KPS score
Patient age, despite being a significant factor in multivari-
ate analysis, did not provide significantly distinct survival
groups when used as either the primary or secondary strat-
ification criteria because of the small number of patients
less than 50 years old. Primary stratification by previous
WBI and secondary stratification by KPS score provided
four groups of patients with significantly distinct median
survival estimates. WBI had the most significant negative
impact on survival, decreasing median survival from
14.7 months (IQR 6.3–22.8 months) for patients who did
not receive WBI to 5.7 months (IQR 3.1–11.6 months) for
those who did receive WBI (Fig. 6). Secondary stratifica-
tion by KPS score within these two groups showed the
cumulative effect of both significant prognosticators on
survival. For recipients of WBI, the greatest impact of
KPS was seen between patients scoring <80 and those
scoring 80–100, p value 0.005 (Fig. 7). KPS scores below
80 decreased median survival to 5.0 months compared with
15.5 months for patients scoring 80–100 (Fig. 6). For pa-
tients who did not receive previous WBI, KPS score had a
similar effect on median survival with the greatest impact
seen between patients scoring <70 and those scoring 70–
100, p value <0.001 (Fig. 7b). Scores below 70 decreased
median survival to 3.5 months while scores 70–100 result-
ed in the longest median survival of any group at
19.5 months (Fig. 6).
Discussion
The observed 7.3-month overall median survival for pa-
tients receiving SRS for SBME in the present study is
nearly identical to the 7.23-month overall median sur-
vival observed in the multi-institution RTOG analysis
that led to the creation of the DS-GPA [10]. Sperduto
et al. reported on 4259 patients treated for initial brain
metastasis with various combinations of surgery, WBI,
Table 4 One- and two-year actuarial survival of significant
prognosticator groups
Prognostic factor One-year Two-year
WBI No 57.7% 23.0%
Yes 22.6% 8.1%
KPS score 90–100 76.9% 15.4%
70–80 33.3% 19.0%
<70 15.1% 3.0%
RPA class 1 48.0% 16.0%
2 40.0% 20.0%
3 12.1% 3.03%
Age <50 6.25% 6.25%
>50 38.9% 13.9%
Fig. 6 Subgroup analysis defined by previous WBI and KPS score
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and SRS [10]. The percentage of patients in the present
study who received previous WBI is 70%, similar to the
76% of patients in the RTOG analysis who received
WBI. The current study group demonstrated poorer av-
erage pretreatment performance status than the RTOG
group with 14.8% KPS 90–100 compared with 41.6%
in the RTOG group and 37.5% KPS <70 compared with
14.9% in the RTOG group (Table 5). Interestingly, pa-
tients in the current study who received SRS for SBME,
with treatment history similar to the Sperduto et al.
study group treated for FBME, experienced nearly iden-
tical overall median survival despite a lower average
performance status.
Our results are consistent with previous reports of SRS
for SBME. Our overall median survival is comparable to
Kurtz et al. who reported a median survival of 11.7 months
after SRS for SBME in a group of healthier patients (87%
ECOG 0–1/KPS 70–100), most of whom received WBI
for FBME (81.1%) [11]. Kurtz et al. reported RPA class
as a significant prognosticator for survival following
SBME [11]. We also found RPA to be significant for
predicting survival from SBME in univariate analysis,
but not in multivariate analysis. KPS was the most signif-
icant factor in our database in multivariate analysis and
represents a powerful and simple prognosticator for
SBME. KPS has consistently proven to be a significant
prognosticator in all indices for both first and second
brain metastatic events [6–10].
Our series compares favorably (median survival of
14.7 months) for patients who did not receive previous
WBI treated with second-course SRS for SBME to
Minnit i et al . who reported median survival of
10.3 months [12]. Additionally, our series is comparable
(median survival of 5.7 months) for patients who did re-
ceive previous WBI treated with SRS for SBME to Harris
et al. who reported median survival of 5.9 months [13].
WBI for FBME has not improved survival in randomized
trials [14–16] over surgery or SRS alone. A recent ran-
domized trial for patients with one to three brain metas-
tases suggest that WBI provides no survival benefit over
SRS alone for treatment of FBME. Greater cognitive de-
cline was associated with WBI than with SRS alone [17].
Our study suggests that previous WBI also decreases me-
dian survival for patients treated with SRS for SBME. It
is not clear if WBI directly affects survival due to de-
crease in KPS secondary to decline in cognitive function
or is an affect of selection for more advanced disease
requiring WBI for FBME and cannot be addressed in
the current study.
Conclusion
KPS is the most significant prognosticator of survival
from SBME when treated with SRS. Use of WBI for
FBME treatment was associated with significant survival
decrement from the time of SBME treatment with SRS.
Median survival in our series of patients treated with
SRS for SBME is comparable to that of FBME series.
However, our results do not account for the inherent
selection bias of retrospective studies and future pro-
spective trials should verify these observations.
Fig. 7 a Kaplan-Meier overall
survival estimates for WBI
patients by KPS score
(P = 0.005). b Kaplan-Meier
overall survival estimates for no.
of WBI patients by KPS score
(P = 0.0001)
Table 5 KPS comparison: current study vs Sperduto et al. RTOG
analysis [10]
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